To study the effects of Rheum officinale (RO) on epidermal growth factor (EGF) in renalhypertrophy in the diabetic rats were induced by streptozotocin. The results showed that renal hypertro-phy occurred in the diabet...To study the effects of Rheum officinale (RO) on epidermal growth factor (EGF) in renalhypertrophy in the diabetic rats were induced by streptozotocin. The results showed that renal hypertro-phy occurred in the diabetic rats, but not in the RO-treated rats. Urine EGF was 38.2 16. 6 ng/24 h atday 28 in the control, and it was signiticantly increased from day 7 in the diabetic rats (477. 8 187. 2 ng/24 h at day 7, 328. 2 153. 9 ng/24 h at day 28) , while in the RO-treated rats it was significantly less thanthat in the diabetic rats (282. 2 112. 5 ng/24 h at day 7, 258. 3 72. 3 ng/24 h at day 28) . Moreover,glomerular filtration rate and renal blood flow reduced in RO-treated diabetic rats as compared with strep-tozotocin diabetic rats. Because kidney is the main source of urine EGF and EGF has been shown to in-duce renal growth both in vitro and in vivo. It is indicated that EGF may be able to initiate renal hypertro-phy in diabetic rats, and the effect of RO on the renal hypertrophy is probably relative to the inhibition ofrenal EGF production resulted from RO treatment.展开更多
OBJECTIVE: To investigate the effects of the mixed endothelin receptor antagonist, bosentan, combined with the long-acting calcium channel blocker, amlodipine, compared to the angiotensin-converting enzyme inhibitor, ...OBJECTIVE: To investigate the effects of the mixed endothelin receptor antagonist, bosentan, combined with the long-acting calcium channel blocker, amlodipine, compared to the angiotensin-converting enzyme inhibitor, cilazapril, on the progressive renal injury in spontaneous hypertensive rats (SHR) with diabetes. METHODS: Diabetic hypertensive rats (SHR-DM) were induced by streptozotozin injected in male SHR (7-week-old),and divided into an untreated and three treated groups: 1) cilazapril treated group; 2) bosentan+amlodipine treated group; and 3) amlodipine treated group. Wistar Kyoto rats (WKY) and SHR rats served as normotensive and hypertensive control, respectively. The mean arterial blood pressure, renal function, endothelin and angiotensin II levels as well as the protein expression of renal extracellular matrix components and transforming growth factor (TGF)-beta1 were determined at the end of the 4th week. RESULTS: Mean arterial blood pressure significantly increased in SHR and SHR-DM rats compared to WKY rats. All the therapies reduced the blood pressure to normal levels. However, the enhanced urinary protein excretion, the decreased creatinine clearance as well as the increased plasma and intrarenal endothelin and angiotens in II levels were found in the untreated SHR-DM and prevented by treatment with bosentan+amlodipine and cilazapril. Similarly, these two kinds of therapies in SHR-DM abolished the overexpression of renal TGF-beta1 by Western blot analysis and reduced the accumulation of collagen type IV, laminin and fibronectin proteins by an immunochemical approach. Amlodipine monotherapy had no detectable effects on the above parameters. CONCLUSION: Bosentan combined with amlodipine can offer similar renoprotective effects on that of cilazapril and may be a potent therapy to attenuate renal injury by reducing renal protein levels of TGF-beta1 in diabetes with a hypertensive state.展开更多
文摘To study the effects of Rheum officinale (RO) on epidermal growth factor (EGF) in renalhypertrophy in the diabetic rats were induced by streptozotocin. The results showed that renal hypertro-phy occurred in the diabetic rats, but not in the RO-treated rats. Urine EGF was 38.2 16. 6 ng/24 h atday 28 in the control, and it was signiticantly increased from day 7 in the diabetic rats (477. 8 187. 2 ng/24 h at day 7, 328. 2 153. 9 ng/24 h at day 28) , while in the RO-treated rats it was significantly less thanthat in the diabetic rats (282. 2 112. 5 ng/24 h at day 7, 258. 3 72. 3 ng/24 h at day 28) . Moreover,glomerular filtration rate and renal blood flow reduced in RO-treated diabetic rats as compared with strep-tozotocin diabetic rats. Because kidney is the main source of urine EGF and EGF has been shown to in-duce renal growth both in vitro and in vivo. It is indicated that EGF may be able to initiate renal hypertro-phy in diabetic rats, and the effect of RO on the renal hypertrophy is probably relative to the inhibition ofrenal EGF production resulted from RO treatment.
文摘【目的】探讨表皮生长因子受体（ErbB4）在糖尿病大鼠海马区星形胶质细胞中的表达及意义。【方法】SD 大鼠单次腹腔注射链脲佐菌素（STZ）诱发实验性1型糖尿病，检测 ErbB4和胶质纤维酸性蛋白（GFAP）在海马区星形胶质细胞中的表达；高糖孵育星形胶质细胞，观察 ErbB4在细胞中的变化。【结果】与对照组相比，实验性1型糖尿病大鼠海马区 GFAP 阳性的星形胶质细胞数目明显增加（ P ＜0．05），ErbB4阳性的星形胶质细胞数目明显减少（ P ＜0．05），ErbB4／GFAP 双标阳性细胞明显低于对照组（ P ＜0．05）。在培养的原代星形胶质细胞，高糖增加细胞活性（P ＜0．05），且明显地降低 ErbB4蛋白表达（ P ＜0．05），但不改变其分布。【结论】糖尿病海马区星形胶质细胞 ErbB4蛋白的表达明显降低，高糖可能是诱导糖尿病海马区星形胶质细胞 ErbB4蛋白表达减少的原因。
基金ThisresearchworkwassupportedbyMinistryofPublicHealthandShanghaiBairenProjectFoundation (No .98BR0 3 8)
文摘OBJECTIVE: To investigate the effects of the mixed endothelin receptor antagonist, bosentan, combined with the long-acting calcium channel blocker, amlodipine, compared to the angiotensin-converting enzyme inhibitor, cilazapril, on the progressive renal injury in spontaneous hypertensive rats (SHR) with diabetes. METHODS: Diabetic hypertensive rats (SHR-DM) were induced by streptozotozin injected in male SHR (7-week-old),and divided into an untreated and three treated groups: 1) cilazapril treated group; 2) bosentan+amlodipine treated group; and 3) amlodipine treated group. Wistar Kyoto rats (WKY) and SHR rats served as normotensive and hypertensive control, respectively. The mean arterial blood pressure, renal function, endothelin and angiotensin II levels as well as the protein expression of renal extracellular matrix components and transforming growth factor (TGF)-beta1 were determined at the end of the 4th week. RESULTS: Mean arterial blood pressure significantly increased in SHR and SHR-DM rats compared to WKY rats. All the therapies reduced the blood pressure to normal levels. However, the enhanced urinary protein excretion, the decreased creatinine clearance as well as the increased plasma and intrarenal endothelin and angiotens in II levels were found in the untreated SHR-DM and prevented by treatment with bosentan+amlodipine and cilazapril. Similarly, these two kinds of therapies in SHR-DM abolished the overexpression of renal TGF-beta1 by Western blot analysis and reduced the accumulation of collagen type IV, laminin and fibronectin proteins by an immunochemical approach. Amlodipine monotherapy had no detectable effects on the above parameters. CONCLUSION: Bosentan combined with amlodipine can offer similar renoprotective effects on that of cilazapril and may be a potent therapy to attenuate renal injury by reducing renal protein levels of TGF-beta1 in diabetes with a hypertensive state.
